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Abstract
Background: Risk of morbidity and mortality in patients with severe heart failure (HF) is reduced by blockade of
aldosterone receptors with spironolactone. However, benefits of spironolactone are potentially limited by treatment
compliance and adverse events profile. The aim of this study was to estimate use of spironolactone by patients
with HF, incidence of key adverse events, and patient compliance.
Methods: This study was performed using data from the Quebec provincial medical and drug plans (Régie de
l’Assurance Maladie du Québec, RAMQ) for patients who had a diagnosis of HF. Relative incidence of gynecomastia
and hyperkalemia was estimated for users and non-users of spironolactone. Treatment adherence was estimated
for users of spironolactone and compared to adherence with angiotensin converting enzyme (ACE) inhibitors, beta-
blockers (b-blockers), and angiotensin receptor blockers (ARBs).
Results: RAMQ data were obtained for a total of 82,018 patients with a diagnosis of HF. Of these patients, 59.9%
used an ACE inhibitor, 59.5% used a beta-blocker, 28.4% used an ARB, and 15.1% (n = 12,344) used spironolactone.
Despite underestimation due to limitation of the database, the documented incidence of hyperkalemia (3.3%
versus 1.4%) and gynecomastia (1.8% versus 0.7%) was significantly higher in spironolactone users than non-users
(p < 0.001). Treatment compliance was significantly lower with spironolactone compared to ACE inhibitors, b-
blockers, and ARBs (45.6% versus 56.1%, 59.7%, and 57.0%, respectively; p < 0.001). Persistence to treatment over a
one-year period was also lower with spironolactone compared to ACE inhibitors, b-blockers, and ARBs (50.7%
versus 64.5%, 70.4%, and 66.3%, respectively; p < 0.001).
Conclusion: Use of spironolactone is associated with an incidence of adverse events, which may have an impact
on treatment compliance.
Background
Heart failure (HF) is a chronic condition defined as the
inability of the heart to maintain a sufficient pumping
activity to meet the body’s metabolic demands under nor-
mal filling pressure [1]. It is usually characterized by
breathlessness (including orthopnea and dyspnea), effort
intolerance, swelling of the legs, and fluid retention [2]. In
Canada, HF affects over 500,000 individuals, with approxi-
mately 50,000 incident cases diagnosed yearly [3]. A retro-
spective Canadian study comprising 72 patients who had
two or more visits to a heart failure clinic revealed that
71% and 21% of subjects were having a severe HF (NYHA
class III and IV respectively, with a mean ejection fraction
of 31%) [4]. HF is associated with a substantial clinical and
economical burden. In Canada, more than 54,330 patients
were hospitalized for HF between 2005 and 2006. More-
over, 4,430 Canadians with HF died in 2004, representing
2% of all deaths [5]. The average cost incurred by HF
patients during their last six months of life was $27,983 in
Canadian dollars in 2006 [6].
Aldosterone, a steroid hormone known to enhance
sodium retention and potassium secretion, plays a major
role in the pathophysiology of heart failure (HF). Accord-
ing to the results of the Randomized Aldactone Evaluation
Study (RALES), the use of spironolactone, a competitive
aldosterone antagonist, an angiotensin converting enzyme
(ACE) inhibitor, a loop diuretic, and in most cases digoxin,
significantly reduces the risk of mortality and morbidity in
patients with severe HF (NYHA class III-IV, LVEF ≤35%)
[7]. Results of this randomized trial suggested that adding
spironolactone to standard treatment for severe HF
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hospitalization rates due to cardiac conditions. In fact,
plasma aldosterone concentrations in HF patients may
reach 20 times the normal level, because of both increased
aldosterone production and decreased rate of hepatic
clearance [8]. Thus, ACE inhibitors are not sufficient to
suppress the production of aldosterone in HF patients,
hence the importance of adding an aldosterone antagonist,
such as spironolactone, to severe HF therapy [9].
However, spironolactone is associated with serious
adverse events, including hyperkalemia and gynecomas-
tia [10,11]. Consequently, clinical benefits related to the
use of spironolactone are potentially limited by the
adverse events profile, which may lead to premature
treatment cessation and poor treatment adherence.
The purpose of this study was to estimate, in real clinical
practice, the utilization rate of spironolactone in patients
with HF, the incidence of key adverse events (hyperkale-
mia and gynecomastia), and patient adherence to spirono-
lactone in terms of compliance and persistence.
Methods
This study was performed using data from the database
of the Quebec provincial health plans (R é g i ed el ’Assur-
ance Maladie du Québec, RAMQ). Like other Canadian
provinces, Quebec has a universal health care program
that covers physician services and hospitalization for the
entire population. This universal health program is com-
plemented, for a large proportion of the population, by a
public drug plan. The provincial drug reimbursement
program covers all people aged 65 and over, beneficiaries
of the social assistance program, and individuals who do
not have access to a private medication insurance plan.
As opposed to the health care plan, for which all costs
are covered, the drug plan involves limited financial par-
ticipation on the part of the beneficiaries. More than 40%
of Quebec’s population is covered by the drug program
[12].
The RAMQ medical services database contains informa-
tion from physicians’ claims for services provided within
and outside the hospital. The RAMQ pharmaceutical ser-
vices database includes information from pharmacists’
claims for dispensed medications reimbursed by the pro-
gram, but not for medications received in a hospital. In
addition, data obtained from the RAMQ include an
encrypted patient identifier, which enables linkage of indi-
vidual patient information while preserving anonymity.
Because patient data used in this study were anonymous,
ethical approval was not required for data analyses.
Data on medical and pharmaceutical services from
January 2000 to September 2008 were obtained from
the RAMQ for patients who had a diagnosis of HF (The
International Classification of Diseases, Ninth Revision:
ICD-9 codes: 4280 - 4289) [13] during that period.
Patient characteristics were described in terms of
gender, age, and comorbidities. Comorbidity level was
estimated by calculating a chronic disease score, based
on the Von Korff score, and updated to account for the
medications introduced since its initial development
[14]. Occurrences of selected medications use during
the study period were used to calculate the chronic dis-
ease score. Use of spironolactone, ACE inhibitors, beta-
blockers (b-blockers), and angiotensin receptor blockers
(ARBs) was also estimated. In addition, use of spirono-
lactone with an ACE inhibitor, an ARB, or a b-blocker
was defined as concomitant when the usage overlap per-
iod for the two medications was at least 60 days.
Relative incidence of adverse events associated with the
use of spironolactone, such as gynecomastia or mastopa-
thy (ICD-9 codes: 6110 - 6119) and hyperkalemia (ICD-9
code: 2767) [13], was estimated by the occurrence of the
corresponding ICD-9 codes found in the medical services
data for users and non-users of spironolactone.
Treatment adherence was estimated for initial users of
standard therapy (ACE inhibitors, ARBs, or b-blockers)
or spironolactone. Patients were considered new users if
the first script for one of these treatments had not been
preceded by any other script for the same treatment in
the 12 previous months. In this analysis, treatment adher-
ence comprises two specific dimensions: compliance to
treatment and persistence to treatment. Compliance
refers to the consistency and accuracy with which the
patient follows the recommended treatment regimen,
while persistence represents the long-term continuation
of treatment.
For each study subject, treatment compliance was esti-
mated by calculating the ratio of effective treatment dura-
tion over expected treatment duration. Effective treatment
duration was estimated by the quantity of medication
received and the corresponding number of days of treat-
ment. Treatment compliance was estimated over a one-
year period. Patients were considered compliant if their
compliance ratio was equal to or greater than 80%. In a
complementary analysis, patients were considered compli-
ant if their compliance ratio was equal to or greater than
50%.
Treatment persistence was estimated over a 3-, 6-, and
12-month period. Patients were considered persistent for
as long as the treatment (spironolactone, ACE inhibitors,
ARBs, or b-blockers) had not definitively ceased. Treat-
ment cessation was determined when the patients had
not received treatment for at least six months.
Differences in incidence of adverse events in spirono-
lactone users and non users were tested for significance
using Pearson’s chi square test. This statistical test was
also performed to compare treatment compliance and
persistence with spironolactone and standard therapy
(ACE inhibitors, ARBs, b-blockers).
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During the period from January 1, 2000 to September
30, 2008, a total of 238,721 patients had received at
least one diagnosis of HF. In accordance with the
RAMQ’s restrictions on the number of subjects available
for analysis by external parties, data were obtained on a
random sample of 82,018 of these patients. Of this sam-
ple, 15.1% (n = 12,344) used spironolactone. There was
a higher proportion of men among spironolactone users,
as opposed to the overall HF group, where the propor-
tion of women was higher. In addition, comorbidity
level, estimated by the modified Von Korff score, was
higher for patients using spironolactone. A large propor-
tion of spironolactone users received concomitant treat-
ment with ACE inhibitors and b-blockers, and to a
lesser extent with ARBs (Table 1).
Incidence of hyperkalemia, breast complications in
men, and more specifically gynecomastia, was signifi-
cantly higher in spironolactone users than in non-users
(Table 2).
Over a one-year period, treatment compliance was sig-
nificantly lower with spironolactone compared to ACE
inhibitors, b-blockers, and ARBs, according to both 80%
and 50% thresholds (Table 3). Moreover, persistence to
treatment after 3-, 6-, and 12-month periods was also
lower with spironolactone compared to ACE inhibitors,
b-blockers, and ARBs (Table 4).
Diagnosis of HF was received after a diagnosis of
acute myocardial infarction (AMI) for 9,288 (11.3%) of
the HF patients. Of these HF post-AMI patients, 1,016
(10.9%) used spironolactonea f t e rt h ed i a g n o s i sw a s
received, while only 686 (7.4%) patients used spironolac-
tone in the first year following the diagnosis. Of the HF
post-AMI patients, 45.4% were compliant over a one-
year period, based on the 80% threshold, and 47.6%
showed persistence to treatment after a 12-month
period.
Discussion
Although spironolactone has proven beneficial for
patients with HF, only a small proportion of HF
patients in this study (15.1%) used this medication. As
previously reported [7], this study found that spirono-
lactone use was associated with higher incidence of
adverse events, including hyperkalemia and gyneco-
mastia. Treatment adherence was less than optimal for
all medications considered in this analysis, particularly
for spironolactone. In fact, both compliance and per-
sistence with spironolactone were significantly lower
compared to standard therapies (ACE inhibitors, b-
b l o c k e r s ,o rA R B s ) .S i m i l a r l y ,t r e a t m e n tp e r s i s t e n c e
related to spironolactone was found to be a major
i s s u ei nt h es t u d yb yB o u v ya n da l . ,w h e r e4 0 . 8 %a n d
58.8% of patients discontinued treatment after 6
months and 7 years, respectively [10].
Table 1 Patient characteristics
CHF
n = 82 018
CHF using
spironolactone
n = 12,344
Age group
<20 518 (0.6%) 11 (0.1%)
20-39 1,366 (1.7%) 62 (0.5%)
40-59 6,114 (7.5%) 716 (5.8%)
60-79 31,499
(38.4%)
5,093 (41.3%)
80+ 42,521
(51.8%)
6,462 (52.3%)
Average age (SD) 77.2 (14.1) 78.5 (11.4)
Gender
- male 39,132
(47.7%)
6,368 (51.6%)
- Female 42,886
(52.3%)
5,976 (48.4%)
Average Von Korff score
(SD)
7.6 (3.4) 8.8 (2.9)
Selected drug use
- ACE 49,140
(59.9%)
9,493 (76.9%)
- ARB 23,326
(28.4%)
4,455 (36.1%)
- b-blocker 48,772
(59.5%)
9,260 (75.0%)
Concomitant use with
- ACE 6,702 (54.3%)
- ARB 2,654 (21.5%)
- b-blocker 7,217 (58.5%)
Table 2 Incidence of adverse events
Spironolactone
users
Spironolactone
non-users
Hyperkalemia 408/12,344
(3.3%)
955/69,674
(1.4%)*
Breast complications in men 158/6,368
(2.5%)
380/32,764
(1.2%)*
Breast hypertrophy in men
(gynecomastia)
117/6,368
(1.8%)
233/32,764
(0.7%)*
* p < 0.001 (Pearson’s chi square test).
Table 3 Treatment compliance
Compliance
50% 80%
ACE 66.4% 56.1%
ARB 68.1% 57.0%
b-blockers 71.1% 59.7%
Spironolactone 58.4%* 45.6%*
* Spironolactone versus ACE, ARB and b-blockers: p < 0.001 (Pearson’s chi
square test)
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it enabled the inclusion of a very large number of subjects
who are assumed to accurately represent a real-world clin-
ical setting, contrary to a clinical trial with a small sample
size and controlled clinical environment. However, as in
other studies based on administrative databases, there are
some inherent limitations. It is assumed that the reim-
bursed medications retrieved from the databases were
taken by the patient, although this may not always be the
case. This could result in overestimation of treatment
adherence. Moreover, medications received while hospita-
lized and medications that were not reimbursed by the
drug plan were not taken into account.
Another limitation of this study is related to the use of
ICD-9 codes to identify patients with HF as well as
occurrence of hyperkalemia and breast complications. In
Quebec, physicians are not required to record an ICD-9
code when meeting their patients, although the vast
majority of them do. In addition, because only a single
ICD-9 code can be recorded on the form for each claim
submitted to the RAMQ for reimbursement of a medi-
cal service, the prevalence of a specific diagnosis can be
underestimated when patients present more than one
medical condition. For example, the diagnosis of gyne-
comastia in HF patients may not be captured when a
diagnosis of HF was first reported. In fact, the incidence
of gynecomastia in spironolactone users in the present
study (1.8%) was much lower than that reported in the
RALES study (9.0%) [7]. As opposed to data from clini-
cal studies, the severity of adverse events is unknown in
studies based on claims data. For example, cases of ser-
ious hyperkalemia (>6 mmol/L) were reported in the
RALES study, whereas only the overall incidence of
hyperkalemia could be estimated in the present study
[7]. Moreover, studies conducted by the RALES investi-
gators found that hyperkalemia was a dose-dependent
effect of spironolactone, as well as gynecomastia, and
required monitoring of the patient [7,15]. This monitor-
ing, which includes serum creatinine and potassium
measurements, must have been reinforced in the present
study population, as most patients were older than 60
and were susceptible to take concomitant medications
and therefore, to require a spironolactone dose
adjustment. For example, non-steroidal anti-inflamma-
tory drugs (NSAIDs) prescribed in rheumatoid arthritis
and in other immune diseases may exacerbate hyperka-
lemia when used with potassium sparing diuretics such
as spironolactone [16,17]. However, these monitoring
measurements are not available in RAMQ data. As the
purpose of the present study was to assess the global
incidence of gynecomastia and hyperkalemia, treatment
regimen has not been considered. Further studies are
needed to evaluate the impact of the treatment regimen
on the incidence of these side effects in Canadian real-
life setting. Furthermore, although digitalis, diuretics
and nitrates are also used in severe HF, they have not
been considered in the present study. However, as there
i sa m p l ee v i d e n c es u p p o r t i n gt h eu s eo fb-blockers,
ACE-I and/or ARB in patients with heart failure, which
include current guidelines [18-20], results of this analy-
sis could give a good estimate of spironolactone use in a
real-life context despite study limitations.
Conclusion
The analysis results suggest that the use of spironolac-
tone is associated with an incidence of adverse events,
which may have an impact on treatment compliance.
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